These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 36672350)

  • 1. Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers.
    Limsakul P; Choochuen P; Charupanit G; Charupanit K
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Markers in Tyrosine Kinases Specific to Basal-like 2 Subtype of Triple-Negative Breast Cancer.
    Limsakul P; Choochuen P; Jungrungrueang T; Charupanit K
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a minimum number of genes to predict triple-negative breast cancer subgroups from gene expression profiles.
    Akhouayri L; Ostano P; Mello-Grand M; Gregnanin I; Crivelli F; Laurora S; Liscia D; Leone F; Santoro A; Mulè A; Guarino D; Maggiore C; Carlino A; Magno S; Scatolini M; Di Leone A; Masetti R; Chiorino G
    Hum Genomics; 2022 Dec; 16(1):70. PubMed ID: 36536459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance.
    Hill DP; Harper A; Malcolm J; McAndrews MS; Mockus SM; Patterson SE; Reynolds T; Baker EJ; Bult CJ; Chesler EJ; Blake JA
    BMC Cancer; 2019 Nov; 19(1):1039. PubMed ID: 31684899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women.
    Tseng LM; Chiu JH; Liu CY; Tsai YF; Wang YL; Yang CW; Shyr YM
    Breast Cancer Res Treat; 2017 Jun; 163(2):241-254. PubMed ID: 28299476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
    Bareche Y; Venet D; Ignatiadis M; Aftimos P; Piccart M; Rothe F; Sotiriou C
    Ann Oncol; 2018 Apr; 29(4):895-902. PubMed ID: 29365031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
    Lehmann BD; Bauer JA; Chen X; Sanders ME; Chakravarthy AB; Shyr Y; Pietenpol JA
    J Clin Invest; 2011 Jul; 121(7):2750-67. PubMed ID: 21633166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer stem cells are prevalent in the basal-like 2 and mesenchymal triple-negative breast cancer subtypes
    Olsson M; Larsson P; Johansson J; Sah VR; Parris TZ
    Front Cell Dev Biol; 2023; 11():1237673. PubMed ID: 37771376
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
    Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
    Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes.
    Yoo TK; Kang J; Lee A; Chae BJ
    Breast Cancer Res Treat; 2022 Feb; 191(3):599-610. PubMed ID: 35018542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting triple-negative breast cancer: A clinical perspective.
    Popovic LS; Matovina-Brko G; Popovic M; Punie K; Cvetanovic A; Lambertini M
    Oncol Res; 2023; 31(3):221-238. PubMed ID: 37305385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
    Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
    PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype.
    Harano K; Wang Y; Lim B; Seitz RS; Morris SW; Bailey DB; Hout DR; Skelton RL; Ring BZ; Masuda H; Rao AUK; Laere SV; Bertucci F; Woodward WA; Reuben JM; Krishnamurthy S; Ueno NT
    PLoS One; 2018; 13(10):e0204513. PubMed ID: 30312311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes.
    Basho RK; Zhao L; White JB; Huo L; Bassett RL; Mittendorf EA; Thompson A; Litton JK; Ueno N; Arun B; Lim B; Valero V; Tripathy D; Zhang J; Adrada BE; Santiago L; Ravenberg E; Seth S; Yam C; Moulder SL; Damodaran S
    JCO Precis Oncol; 2024 Mar; 8():e2300124. PubMed ID: 38484209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer.
    Kumar S; Bal A; Das A; Loriya I; Khare S; Bhattacharya S; Singh G
    Breast Cancer Res Treat; 2021 Jun; 187(3):625-633. PubMed ID: 33954864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Classification Models for Triple Negative Breast Cancer Subtype Using Machine Learning.
    Bissanum R; Chaichulee S; Kamolphiwong R; Navakanitworakul R; Kanokwiroon K
    J Pers Med; 2021 Sep; 11(9):. PubMed ID: 34575658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.
    Masuda H; Baggerly KA; Wang Y; Zhang Y; Gonzalez-Angulo AM; Meric-Bernstam F; Valero V; Lehmann BD; Pietenpol JA; Hortobagyi GN; Symmans WF; Ueno NT
    Clin Cancer Res; 2013 Oct; 19(19):5533-40. PubMed ID: 23948975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response.
    Thompson KJ; Leon-Ferre RA; Sinnwell JP; Zahrieh DM; Suman VJ; Metzger FO; Asad S; Stover DG; Carey L; Sikov WM; Ingle JN; Liu MC; Carter JM; Klee EW; Weinshilboum RM; Boughey JC; Wang L; Couch FJ; Goetz MP; Kalari KR
    NAR Cancer; 2022 Jun; 4(2):zcac018. PubMed ID: 35734391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy.
    Masuda H; Harano K; Miura S; Wang Y; Hirota Y; Harada O; Jolly MK; Matsunaga Y; Lim B; Wood AL; Parinyanitikul N; Jin Lee H; Gong G; George JT; Levine H; Lee J; Wang X; Lucci A; Rao A; Schweitzer BL; Lawrence OR; Seitz RS; Morris SW; Hout DR; Nakamura S; Krishnamurthy S; Ueno NT
    JCO Precis Oncol; 2022 Mar; 6():e2000368. PubMed ID: 35294223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
    Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
    Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.